<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0016-3813</journal-id>
<journal-title><![CDATA[Gaceta médica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. Méd. Méx]]></abbrev-journal-title>
<issn>0016-3813</issn>
<publisher>
<publisher-name><![CDATA[Academia Nacional de Medicina de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0016-38132019000100015</article-id>
<article-id pub-id-type="doi">10.24875/gmm.18004407</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Valor terapéutico potencial de medicamentos en México: el caso de los antibióticos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mino-León]]></surname>
<given-names><![CDATA[Dolores]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Carvajal]]></surname>
<given-names><![CDATA[Ixzel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peredo-Silva]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Búrbano-Martínez]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Morelos  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional Autónoma de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,aff4  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2019</year>
</pub-date>
<volume>155</volume>
<numero>1</numero>
<fpage>15</fpage>
<lpage>19</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0016-38132019000100015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0016-38132019000100015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0016-38132019000100015&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La relevancia de los medicamentos para la salud depende de su calidad, acceso y correcto uso.  Objetivos: Determinar el valor terapéutico potencial de los antibióticos no incluidos en la lista de medicamentos esenciales (LME) de la Organización Mundial de la Salud pero que forman parte del Cuadro Básico de Medicamentos (CBM) de la Secretaría de Salud de México y categorizarlos por su valor intrínseco.  Método: Análisis descriptivo de los antibióticos no incluidos en la LME de la Organización Mundial de la Salud 2013, revisión de la literatura para obtener evidencia de eficacia y seguridad y aplicación de escala de calidad y de valor intrínseco.  Resultados: Se identificaron 452 resúmenes para 19 antibióticos, se eliminaron 56.9 %. In extenso se revisaron 195 ensayos clínicos; 37.9 % fueron de calidad y se determinó valor intrínseco; 54 % fueron estudios de superioridad y 46 % de no inferioridad o equivalencia; 32 % de los antibióticos fueron clasificados sin valor intrínseco y aproximadamente 50 % fueron dudosos.  Conclusión: Una elevada proporción de antibióticos del CBM tuvo valor intrínseco dudoso o nulo, lo que favorece su uso inapropiado, resistencia bacteriana y coloca a la población en riesgo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: The relevance of medications for health depends on their quality, accessibility and appropriate use.  Objective: To determine the potential therapeutic value of antibiotics that are not included in the World Health Organization Essential Medicines List (EML) but that are part of the National Essential Medicines List (NEML) of the Mexican Ministry of Health, and categorize them according to their intrinsic value.  Method: Descriptive analysis of antibiotics not included in the 2013 World Health Organization EML; literature review to obtain efficacy and safety evidence; and application of quality and intrinsic value scales.  Results: Four hundred and fifty-two abstracts were identified for 19 antibiotics; 56.9 % were excluded; 195 clinical trials were reviewed in full-text articles, out of which 37.9 % were of good quality, and intrinsic value was determined; 54 % were superiority studies, whereas 46 % were non-inferiority or equivalence studies; 32 % of the antibiotics were classified without intrinsic value and nearly 50 % were inconclusive.  Conclusion: An elevated proportion of antibiotics of the NEML had uncertain or no intrinsic value, which favors their inappropriate use, bacterial resistance and puts the population at risk.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antibióticos]]></kwd>
<kwd lng="es"><![CDATA[Valor terapéutico]]></kwd>
<kwd lng="es"><![CDATA[Lista de medicamentos esenciales]]></kwd>
<kwd lng="es"><![CDATA[Cuadro básico medicamentos]]></kwd>
<kwd lng="en"><![CDATA[Antibiotics]]></kwd>
<kwd lng="en"><![CDATA[Therapeutic value]]></kwd>
<kwd lng="en"><![CDATA[Essential Medicines List]]></kwd>
<kwd lng="en"><![CDATA[National Essential Medicines List]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[The world medicines situation 2004]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Ginebra, Suiza ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>World Health Organization. The rational use of drugs</collab>
<source><![CDATA[Report of the conference of experts, Nairobi, 25-29 November 1985]]></source>
<year>1987</year>
<publisher-loc><![CDATA[Ginebra, Suiza ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoyle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historical lifetimes of drugs in England:application to value of information and cost-effectiveness analyses]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2010</year>
<volume>13</volume>
<page-range>885-92</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diogene]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What public policies have been more effective in promoting rational prescription of drugs?]]></article-title>
<source><![CDATA[J Epidemiol Community Health]]></source>
<year>2011</year>
<volume>65</volume>
<page-range>87-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rico-Alba]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The fuzzy line between needs, coverage, and excess in the Mexican formulary list:an example of qualitative market width analysis]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2013</year>
<volume>69</volume>
<page-range>949-56</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dreser]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Corbett]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Echániz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de antibióticos en México:revisión de problemas y políticas]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2008</year>
<volume>50</volume>
<page-range>S480-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Floyd]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Psaty]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The potential risks of expedited approval of drugs for acute bacterial infections]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2014</year>
<volume>174</volume>
<page-range>1436-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Navas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Escribano Ráez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Juberías]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Gea]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procedure for the marketing authorization of an antibacterial agent]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>529-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rico-Alba]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The evolution of reference drug lists and clinical practice guidelines in the public health system of a middle-income country]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2014</year>
<volume>78</volume>
<page-range>410-21</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laporte]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Porta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Capella]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug utilization studies:a tool for determining the effectiveness of drug use]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>1983</year>
<volume>16</volume>
<page-range>301-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jadad]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkinson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gavaghan]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the quality of reports of randomized clinical trials:is blinding necessary?]]></article-title>
<source><![CDATA[Control Clin Trials]]></source>
<year>1996</year>
<volume>17</volume>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Selection of essential medicines]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Ginebra, Suiza ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perumal-Pillay]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Suleman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selection of essential medicines for South Africa:an analysis of in-depth interviews with national essential medicines list committee members]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2017</year>
<volume>17</volume>
<page-range>17</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Management Sciences for Health</collab>
<source><![CDATA[MSD-3:Managing access to medicines and health technologies]]></source>
<year>2012</year>
<publisher-loc><![CDATA[EE. UU ]]></publisher-loc>
<publisher-name><![CDATA[Management Sciences for Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozolins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eady]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cunliffe]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Po]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[O'Neill]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community:randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2004</year>
<volume>364</volume>
<page-range>2188-95</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
